menu
    • menu
    [{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Forbion"},{"orgOrder":0,"company":"enGene","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Deep Track Capital"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Adage Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Adage Capital Partners"},{"orgOrder":0,"company":"enGene","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Hercules Capital"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"EG-70","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by enGene

    Menu

    enGene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $60.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            enGene Announces $60 Million Private Placement Financing

                            Details : The proceeds from the financing will used to fund the continued development of EG-70 (detalimogene voraplasmid), which is being evaluated for the BCG-unresponsive non-muscle invasive bladder cancer.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 25, 2024

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $60.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Detalimogene Shows 71% Complete Response Rate in LEGEND Pivotal Cohort Analysis

                            Details : EG-70 (detalimogene voraplasmid) is a IL-12 inhibitor gene therapy, which is being evaluated for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Adage Capital Partners

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            enGene Announces Oversubscribed $200 Million Private Placement Financing

                            Details : The net proceeds will be used for the clinical development of EG-70 (detalimogene voraplasmid) for non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin treatment.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Adage Capital Partners

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hercules Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

                            Details : The financing will be used for the advancement of EG-70 (detalimogene voraplasmid) as an entirely new genetic medicine approach to treat BCG-unresponsive non-muscle invasive bladder cancer.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 22, 2023

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hercules Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Forbion

                            Deal Size : $115.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination A...

                            Details : The net proceeds are expected to be used to fund the clinical development of intravesical EG-70 (detalimogene voraplasmid), a monotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Forbion

                            Deal Size : $115.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladde...

                            Details : EG-70 is a novel non-viral gene therapy encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system. It is being investigated for NMIBC in patients with carcinoma in situ that are BCG-unresponsive.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 14, 2023

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG-70

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BC...

                            Details : EG-70 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 12, 2021

                            Lead Product(s) : EG-70

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            enGene

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            enGene Gets FDA Clearance of IND Application for EG-70

                            Details : The study design consists of an open label dose escalation Phase 1 study to evaluate the safety and tolerability of EG-70 and to determine the recommended Phase 2 dose, followed by a Phase 2 portion to evaluate efficacy and safety.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 02, 2020

                            Lead Product(s) : Detalimogene Voraplasmid

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth